Table 6.
Demographics, clinical characteristics, and treatments of GC/GEJC/EAC patients according to de novo or recurrent disease
| Total | De novo | Recurrent | |
|---|---|---|---|
| Age, years | 682 | 552 | 130 |
| Mean (SD) | 64.6 (10.0) | 65.6 (9.8) | 60.3 (9.6) |
| Median (IQR) | 66 (59–71) | 67 (60–72) | 62 (55–68) |
| Confirmed diagnosis, n (%) | 682 | 552 | 130 |
| GC | 415 (60.9) | 324 (58.7) | 91 (70.0) |
| GEJC | 192 (28.2) | 162 (29.4) | 30 (23.1) |
| EAC | 75 (11.0) | 66 (12.0) | 9 (6.9) |
| Time since diagnosis, months | 625 | 502 | 123 |
| Mean (SD) | 6.3 (13.0) | 3.6 (4.7) | 17.6 (24.8) |
| Median (IQR) | 3 (2–6) | 2 (2–4) | 13 (7–20) |
| Time since advanced diagnosis, months | 629 | 503 | 126 |
| Mean (SD) | 4.8 (7.6) | 3.6 (4.7) | 9.5 (13.2) |
| Median (IQR) | 3 (2–5) | 3 (2–4) | 5 (3–11) |
| Nonpharmacological treatments, n (%) | 682 | 552 | 130 |
| Surgery | 162 (23.8) | 75 (13.6) | 87 (66.9) |
| Radiotherapy | 103 (15.1) | 70 (12.7) | 33 (25.8) |
| Stent | 72 (10.6) | 61 (11.1) | 11 (8.5) |
| Laser therapy | 5 (0.7) | 5 (0.9) | 0 (0.0) |
| None | 400 (58.7) | 382 (69.2) | 18 (13.9) |
| Side effect experienced (> 10%), n (%) | 296 (45.0) | 210 (39.3) | 86 (69.4) |
| Nausea | 186 (62.8) | 128 (61.0) | 58 (67.4) |
| Fatigue | 144 (48.7) | 98 (46.7) | 46 (53.5) |
| Anemia | 106 (35.8) | 72 (34.3) | 34 (39.5) |
| Loss of appetite | 103 (34.8) | 62 (29.5) | 41 (47.7) |
| Vomiting | 97 (32.8) | 52 (24.8) | 45 (52.3) |
| Low white blood cell count | 86 (29.1) | 59 (28.1) | 27 (31.4) |
| Diarrhea | 81 (27.4) | 61 (29.1) | 20 (23.3) |
| Weight loss/gain | 66 (22.3) | 35 (16.7) | 31 (36.1) |
| Low platelet count | 59 (19.9) | 38 (18.1) | 21 (24.4) |
| Numbness in hands and feet | 56 (18.9) | 38 (18.1) | 18 (20.93) |
| Hair loss/thinning | 54 (18.2) | 27 (12.9) | 27 (31.4) |
| Abdominal pain | 30 (10.1) | 15 (7.1) | 15 (17.4) |
| Bothered by side effects, n (%) | 676 | 550 | 126 |
| Not at all | 81 (12.0) | 68 (12.4) | 13 (10.3) |
| A little bit | 212 (31.4) | 180 (32.7) | 32 (25.4) |
| Somewhat | 247 (36.5) | 191 (34.7) | 56 (44.4) |
| Quite a bit | 110 (16.3) | 89 (16.2) | 21 (16.7) |
| Very much | 26 (3.5) | 22 (4.0) | 4 (3.2) |
| EQ-5D-3L utility index | 672 | 544 | 128 |
| Mean (SD) | 0.70 (0.29) | 0.69 (0.29) | 0.77 (0.24) |
| Median (IQR) | 0.78 (0.59–0.93) | 0.76 (0.55–0.89) | 0.89 (0.70–0.94) |
| EQ-VAS | 675 | 550 | 125 |
| Mean (SD) | 58.1 (19.8) | 58.4 (20.2) | 56.6 (18.1) |
| Median (IQR) | 60 (45–75) | 60 (45–75) | 60 (47–70) |
| FACT: Gastric cancer subscale | 677 | 549 | 128 |
| Mean (SD) | 40.9 (14.2) | 41.4 (14.5) | 39.0 (12.6) |
| Median (IQR) | 41 (31–51) | 41 (32–52) | 38 (31–48) |
| FACT: Trial outcome index | 602 | 489 | 113 |
| Mean (SD) | 68.0 (23.6) | 68.8 (24.4) | 64.4 (19.4) |
| Median (IQR) | 68 (53–84) | 69 (54–86) | 65 (53–77) |
| FACT-G | 296 | 244 | 52 |
| Mean (SD) | 56.9 (16.8) | 57.5 (17.5) | 54.4 (13.0) |
| Median (IQR) | 54 (47–67) | 55 (48–69) | 53 (45–62) |
| FACT: Gastric total | 281 | 230 | 51 |
| Mean (SD) | 100.3 (28.9) | 101.2 (30.1) | 96.4 (22.6) |
| Median (IQR) | 97 (82–121) | 98 (83–123) | 97 (81–111) |
EAC Esophageal adenocarcinoma, EQ-5D-3L EuroQol 5-Dimension 3-Level questionnaire, EQ-VAS EuroQol—Visual Analogue Scale, FACT Functional Assessment of Cancer Therapy, FACT-G Functional Assessment of Cancer Therapy – General, FACT-Ga Functional Assessment of Cancer Therapy—Gastric Cancer, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation